|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 30-Jan-2024 |
Dr Reddys Laboratories - Powered by gRevlimid & steady growth in base biz; Maintained BUY with TP Rs 6500 |
India |
Surya Patra |
 |
| 29-Oct-2023 |
Dr Reddys Laboratories - Powered by gRevlimid benefits & steady growth in base biz; Maintain BUY with TP Rs 6200 |
India |
Surya Patra |
|
| 26-Jul-2023 |
Dr Reddys Labs: Best beneficiary of gRevlimid & set for an all-round progress; BUY with raised TP of Rs 6200 |
India |
Surya Patra |
|
| 11-May-2023 |
Dr Reddys Labs (DRRD IN): gRevlimid cashflow drives qualitative growth ahead; BUY with upward revised TP of Rs 6000 |
India |
Surya Patra |
|
| 26-Jan-2023 |
Dr Reddys Laboratories - The biggest beneficiaries of gRevlimid amongst peers; BUY with raised TP Rs5,500 |
India |
Surya Patra |
|
| 29-Oct-2022 |
Dr Reddys Labs - Raining cashflow from gRevlimid drives qualitative growth; BUY with raised TP of Rs 5300 |
India |
Surya Patra |
|
| 28-Jul-2022 |
Dr Reddys Laboratories - US gRevlimid launch to drive value growth starting Sept22; Maintain BUY with TP Rs 5100 |
India |
Surya Patra |
|
| 22-Jun-2022 |
Dr Reddys Laboratories - Laid out ambitious 5 year plan; Could hurt near-term margins: |
India |
Surya Patra |
|
| 20-May-2022 |
Dr Reddys Laboratories - Reemphasizing US focus but beyond traditional generics; Maintain BUY with TP Rs 5250 |
India |
Surya Patra |
|
| 30-Jan-2022 |
Dr Reddys Laboratories - gRevlimid launch in the US is the key trigger; BUY with lowered TP Rs 5630 |
India |
Surya Patra |
|
| 31-Oct-2021 |
Dr Reddys Laboratories - Strong earnings visibility intact: Maintain BUY with TP Rs 6040 |
India |
Surya Patra |
|
| 28-Jul-2021 |
Dr Reddys Laboratories - Strong earnings visibility intact; BUY with TP Rs 6080 |
India |
Pradeep Agrawal |
|
| 16-May-2021 |
Dr Reddy’s Laboratories - Covid vaccine opportunity upgrades earnings by 50%; BUY with raised TP Rs 6125 |
India |
Surya Patra |
|
| 30-Jan-2021 |
Dr Reddy’s Laboratories (DRRD IN) - Business as usual; Strong earnings visibility ahead: Maintain BUY with TP Rs 5800 |
India |
Surya Patra |
|
| 28-Oct-2020 |
Dr Reddy’s Laboratories - Stable quarter; On track for strong growth ahead; Maintain BUY with TP Rs 5800 |
India |
Siam Tiyanont |
|
| 28-Oct-2020 |
Dr Reddy’s Laboratories - Stable quarter; On track for strong growth ahead; Maintain BUY with TP Rs 5800 |
India |
Surya Patra |
|
| 18-Sep-2020 |
Dr Reddy’s Laboratories - Revlimid settlement comes as a big value proposition; Upgrade to BUY with TP Rs 5800 |
India |
Surya Patra |
|
| 30-Jul-2020 |
Dr Reddy’s Laboratories - Visible triggers already priced in: Neutral with TP of Rs 3800 |
India |
Surya Patra |
|
| 21-May-2020 |
Dr Reddy’s Lab - Likely to see margin pressure going ahead |
India |
Surya Patra |
|
| 28-Jan-2020 |
Dr Reddy’s Lab: Focuses on cost containment as sales outlook becomes muted: Neutral, TP Rs 3300 |
India |
Surya Patra |
|
| 04-Nov-2019 |
Dr Reddy’s Lab - Not out of woods yet: Maintain Neutral with TP Rs 2800 |
India |
Surya Patra |
|
| 29-Jul-2019 |
Dr Reddy’s Labs (DRRD IN) - Lacks near-term growth triggers; Maintain NEUTRAL with TP Rs 2850 |
India |
Surya Patra |
|
| 15-Jul-2019 |
Dr Reddy’s Laboratories (DRRD IN) - Relief in gSuboxone litigation; No incremental earnings; NEUTRAL with TP Rs 2850 |
India |
Surya Patra |
|
| 17-May-2019 |
Dr Reddy’s Labs (DRRD IN) - Delay in key product launches moderate growth; NEUTRAL TP Rs 2850 |
India |
Surya Patra |
|
| 01-Feb-2019 |
Dr Reddy’s Laboratories (DRRD IN) - Set for sequential earnings growth; NEUTRAL with TP of Rs 3000 |
India |
Surya Patra |
|
|
|